Agilent Technologies, Inc. · NYSE:A
Agilent Technologies — Investor Presentation (October 2022)
8 slides from Agilent Technologies's investor presentation, Oct 11, 2022
Slide 1: Safe Harbor Statement
Safe Harbor Statement These presentations contain forward-looking statements (including, without limitation, information, and future guidance on the company’s goals, the company’s cell analysis business, priorities, revenue, revenue growth, growth opportunities, new products and solutions, customer
Slide 2: Agilent's "Build and Buy" Growth Strategy
Agilent’s “Build and Buy” Growth Strategy Accelerate Our Momentum in Attractive Market Opportunities z z z Transform Gain Share Enter and Expand Analytical Lab Cancer Diagnostics & High Growth Markets Genomics Innovation Strategic Enablers Digital M&A Geographic Penetration One Agilent Cultu
Slide 3: Why Cell Analysis…
Why Cell Analysis… Unique Opportunity to Address Important Market Challenges • The most debilitating, costly, and lethal diseases are cell-related, mediated, or treated. • Modeling the integrated activities comprised within a living cell is essential for disease research • Advances in cell analysis
Slide 4: Traditional Techniques Evolving with Emerging Live-cell Capabilities
Traditional Techniques Evolving with Emerging Live-cell Capabilities Scientists are using Immunology & the Immune System to Treat Cancer & Fight Infectious Disease $5B(1) Opportunity with Attractive Growth Drivers; 5-7%(2) • Emergence of promising new biologic therapeutic modalities Immunology, Immu
Slide 5: Our Journey
Our Journey Enabling a Deeper Understanding Of The Cellular Environment Agilent has a long history of BioTek Instruments: innovation and leadership in Luxcel Bioscience: Broad plate reader providing tools for life science portfolio, imaging systems, Label-free sensor and chemical analysis across and
Slide 6: Strong Foundation Poised for Future Growth & Expansion
Strong Foundation Poised for Future Growth & Expansion Differentiated Portfolio Targeted at Emerging High-growth Segments FY2021 Product Portfolio End-market Segment Services Pharma/Biopharma Software & Plate Readers $375M+ Academic and Government Accessories Revenue Relative Relative Contribution L
Slide 7: Unique Portfolio Addressing Critical Customer Challenges
Unique Portfolio Addressing Critical Customer Challenges Maintaining Our Growth Momentum Enabling Workflow Solutions Across Techniques, Platforms, and Applications • Greater Insights – more information from same samples, across multiple platforms with integrated data analysis & Agilent Bravo Agilent
Slide 8: October 11, 2022
tS Agilent Trusted Answers
Agilent Technologies — Investor Presentation (October 2022) on 6ix